Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel
immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have
significantly improved the prognosis of B-NHL patients, there are still nearly one-third of
patients who are resistant to initial treatment or relapse after remission. R-CHOP combined
with novel drugs was expected to improve the prognosis. Therefore, this study aimed to
investigate the potential of R-CHOP combined with Orelabrutinib.